Summary of Key Information from the Text:
Here’s a breakdown of the key takeaways from the provided text, focusing on oral semaglutide (Wegovy) and injectable semaglutide:
1. Weight Reduction Efficacy:
* Oral Semaglutide (25mg): Average weight reduction of ~13.6% (rounded to 14%). 79% of participants achieved ≥5% weight reduction (clinically notable).
* Injectable Semaglutide (2.4mg): Average weight reduction of ~14.9% (rounded to 15%). 86% of participants achieved ≥5% weight reduction.
* Overall: The drugs are clinically equivalent in terms of weight reduction, delivering roughly 15% weight loss with long-term persistence (over a year).
2. Adverse Effects (AEs):
* Common to Both: High incidence of gastrointestinal AEs (nausea, vomiting, diarrhea) – affecting roughly ¾ of patients.
* Severity: Most GI AEs are mild to moderate.
* Discontinuation due to AEs: low discontinuation rates (around 7% or less) for both oral and injectable due to GI AEs.
* Oral Specific:
* More skin sensation changes (dysesthesia) – ~5% vs. ~2.5% with injectable.
* Slightly more common gastrointestinal AEs due to dyspepsia (heartburn).
3. Discontinuation Rates:
* Oral Semaglutide: discontinuation rates are roughly three times higher than with injectable semaglutide (at 64-68 weeks/ ~15 months).
* Primary Driver: Not the AE profile, but rather the strict requirements for taking the oral medication.
* Daily dosing.
* Must be taken on an empty stomach.
* 30-minute wait before eating/drinking.
* Must be kept in original container.
* Injectable Semaglutide: Weekly dosing offers more flexibility and perhaps better adherence.
In essence, both forms of semaglutide are effective for weight loss, but the oral formulation presents challenges with adherence due to its strict administration requirements, leading to higher discontinuation rates despite a similar AE profile.
